Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Unicycive Therapeutics, with a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Unicycive Therapeutics’ promising outlook. The company recently held a Type A meeting with the FDA to address a complete response letter for its drug, oxylanthanum carbonate (OLC), used in treating hyperphosphatemia in chronic kidney disease. The meeting focused on resolving a single deficiency related to a third-party vendor, with no concerns about the drug’s preclinical, clinical, or safety data. This progress positions Unicycive to refile by the end of 2025, potentially leading to a PDUFA date in the first half of 2026.
Additionally, Unicycive’s strong cash position of $42 million as of the third quarter of 2025 provides financial stability through 2027, supporting its development efforts. The company’s Phase 2 study of OLC showed significant improvements in patient adherence and satisfaction, with a reduced pill burden and better tolerability compared to existing treatments. These positive clinical outcomes, combined with a strategic financial plan and a clear regulatory path, underpin McCarthy’s optimistic outlook and Buy rating for Unicycive’s stock.
In another report released yesterday, Benchmark Co. also maintained a Buy rating on the stock with a $21.00 price target.